Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

REIMAGINE - Real World Evaluation of Mepolizumab i svær astma opnår ved behandling klinisk remission, en prospektiv undersøgelse (REIMAGINE)

6. november 2026 opdateret af: GlaxoSmithKline

En prospektiv, virkelig verden, interventionsundersøgelse til at evaluere effekten af ​​mepolizumab på opnåelse af klinisk remission hos deltagere med svær astma

This is a prospective, real-world, single arm, global, multi-centre study to evaluate the effect of timely treatment with mepolizumab (NUCALA) to achieve clinical remission in adult participants with severe asthma with an eosinophilic phenotype (SA-EP).

Studieoversigt

Status

Aktiv, ikke rekrutterende

Betingelser

Intervention / Behandling

Undersøgelsestype

Interventionel

Tilmelding (Faktiske)

177

Fase

  • Fase 4

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

      • Kortrijk, Belgien, 8500
        • GSK Investigational Site
      • Liège, Belgien, 4000
        • GSK Investigational Site
    • Alberta
      • Calgary, Alberta, Canada, T3B0M3
        • GSK Investigational Site
      • Calgary, Alberta, Canada
        • GSK Investigational Site
    • Manitoba
      • Winnipeg, Manitoba, Canada, R3L 1Z5
        • GSK Investigational Site
    • Ontario
      • Toronto, Ontario, Canada, M5G 1E2
        • GSK Investigational Site
    • California
      • La Jolla, California, Forenede Stater, 92037
        • GSK Investigational Site
      • Newport Beach, California, Forenede Stater, 92663
        • GSK Investigational Site
    • Colorado
      • Aurora, Colorado, Forenede Stater, 71105
        • GSK Investigational Site
      • Colorado Springs, Colorado, Forenede Stater, 80923
        • GSK Investigational Site
    • Connecticut
      • New Haven, Connecticut, Forenede Stater, 06510
        • GSK Investigational Site
    • Florida
      • Homestead, Florida, Forenede Stater, 33032-8185
        • GSK Investigational Site
      • Jacksonville, Florida, Forenede Stater, 32209
        • GSK Investigational Site
      • Miami, Florida, Forenede Stater, 33125
        • GSK Investigational Site
      • Plantation, Florida, Forenede Stater, 33317
        • GSK Investigational Site
    • Georgia
      • Adairsville, Georgia, Forenede Stater, 30103
        • GSK Investigational Site
      • Columbus, Georgia, Forenede Stater, 31904
        • GSK Investigational Site
    • Kentucky
      • Lexington, Kentucky, Forenede Stater, 40509-1801
        • GSK Investigational Site
      • Owensboro, Kentucky, Forenede Stater, 42301
        • GSK Investigational Site
    • Louisiana
      • New Orleans, Louisiana, Forenede Stater, 34452
        • GSK Investigational Site
    • Maryland
      • Glenn Dale, Maryland, Forenede Stater, 20769
        • GSK Investigational Site
      • Towson, Maryland, Forenede Stater, 21204
        • GSK Investigational Site
    • Michigan
      • Ann Arbor, Michigan, Forenede Stater, 48103
        • GSK Investigational Site
    • Minnesota
      • Linwood, Minnesota, Forenede Stater, 55092
        • GSK Investigational Site
      • Rochester, Minnesota, Forenede Stater, 55905-0001
        • GSK Investigational Site
    • Nevada
      • Henderson, Nevada, Forenede Stater, 89052-5015
        • GSK Investigational Site
    • New York
      • Rochester, New York, Forenede Stater, 14607
        • GSK Investigational Site
      • Schenectady, New York, Forenede Stater, 12308
        • GSK Investigational Site
    • Pennsylvania
      • Philadelphia, Pennsylvania, Forenede Stater, 19140
        • GSK Investigational Site
      • Philadelphia, Pennsylvania, Forenede Stater, 19141
        • GSK Investigational Site
    • South Carolina
      • Union, South Carolina, Forenede Stater, 29379-7409
        • GSK Investigational Site
    • Texas
      • Cypress, Texas, Forenede Stater, 77429-1439
        • GSK Investigational Site
      • Kerrville, Texas, Forenede Stater, 78028
        • GSK Investigational Site
      • McKinney, Texas, Forenede Stater, 75069
        • GSK Investigational Site
      • Brest, Frankrig, 29200
        • GSK Investigational Site
      • Cannes, Frankrig, 06614
        • GSK Investigational Site
      • Lille, Frankrig, 59000
        • GSK Investigational Site
      • Lyon, Frankrig, 69004
        • GSK Investigational Site
      • Strasbourg, Frankrig, 67091
        • GSK Investigational Site
      • Toulouse, Frankrig, 31059
        • GSK Investigational Site
      • Genova, Italien, 16132
        • GSK Investigational Site
      • Monserrato CA, Italien, 09042
        • GSK Investigational Site
      • Naples, Italien, 80131
        • GSK Investigational Site
      • Pieve Di Soligo TV, Italien, 131044
        • GSK Investigational Site
      • Roma, Italien, 00128
        • GSK Investigational Site
      • Roma, Italien, 161
        • GSK Investigational Site
      • Rozzano, Italien, 20089
        • GSK Investigational Site
      • Verona, Italien, 37126
        • GSK Investigational Site
      • Gifu, Japan, 509-6134
        • GSK Investigational Site
      • Kagawa, Japan, 760-0018
        • GSK Investigational Site
      • Tokyo, Japan, 142-8666
        • GSK Investigational Site
      • Tokyo, Japan, 173-8606
        • GSK Investigational Site
      • Tokyo, Japan, 105-0003
        • GSK Investigational Site
      • ?Od?, Polen, 90-153
        • GSK Investigational Site
      • Gdansk, Polen, 80-214
        • GSK Investigational Site
      • Lodz, Polen, 92-213
        • GSK Investigational Site
      • Barcelona, Spanien, 08025
        • GSK Investigational Site
      • Girona, Spanien, 17005
        • GSK Investigational Site
      • Valencia, Spanien, 46015
        • GSK Investigational Site
      • Bonn, Tyskland, 53119
        • GSK Investigational Site
      • Hohenstein-Ernsttal, Tyskland, 9337
        • GSK Investigational Site
      • Schleswig, Tyskland, 53123
        • GSK Investigational Site
    • Hesse
      • Darmstadt, Hesse, Tyskland, 64283
        • GSK Investigational Site
      • Frankfurt am Main, Hesse, Tyskland, 60389
        • GSK Investigational Site
    • North Rhine-Westphalia
      • Aachen, North Rhine-Westphalia, Tyskland, 52074
        • GSK Investigational Site

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  • Participant has a confirmed asthma diagnosis and has been prescribed NUCALA by their physician for the treatment of asthma, as per local label. NUCALA can be initiated up to 7 days prior to study enrollment.
  • No NUCALA use in the 6 months prior to enrollment.
  • Participants with greater than or equal to (≥)60 percentage (%) predicted forced expiratory volume in 1 second (FEV1) and less than or equal to (≤)4 exacerbations per year, as confirmed by the physician.
  • Other local prescription criteria of NUCALA not described above at NUCALA initiation (e.g., local reimbursement criteria).
  • Written informed consent

Exclusion Criteria:

  • Investigator concerns about participant's willingness to adhere to biologic treatment for any reason (e.g., cost, behavior, difficulty with access to healthcare)
  • Participants currently on maintenance OCS or intramuscular corticosteroids.
  • Participants using omalizumab, reslizumab, dupilumab, tezepelumab, or benralizumab within the 6 months prior to enrollment
  • Participants participating in an interventional study with a treatment intervention

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Andet
  • Tildeling: N/A
  • Interventionel model: Enkelt gruppeopgave
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Andet: Group 1

Participants with a clinical diagnosis of Severe asthma prescribed Mepolizumab as part of routine care.

Mepolizumab will be prescribed based on physician decision.

Lung function via spirometry will be collected.

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Percentage (%) of Participants Achieving 4-Component Clinical Remission
Tidsramme: At month 12

4-component clinical remission is defined as (a) No clinically significant asthma exacerbations (b) No OCS use for asthma (c) Well controlled asthma based on an Asthma Control Test (ACT) (d) No clinically significant deterioration of lung function.

At month 12

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Annualized Rates of Clinically Significant Asthma Exacerbations (CSE) and CSE Leading to Hospitalization/ Emergency Room (ER) Visits
Tidsramme: At month 12

CSE is defined as a deterioration in asthma requiring (1) the initiation of systemic corticosteroids and/or (2) an ER visit and/or hospital admission.

At month 12
Percentage of Participants Achieving OCS Sparing Remission
Tidsramme: At month 12

OCS sparing is defined as (a) No clinically significant asthma exacerbations during the period of interest (b) No OCS use for asthma at the time point of interest.

At month 12
Percentage of Participants Achieving 3-Component Clinical Remission
Tidsramme: At month 12

3-component clinical remission is defined as (a) No clinically significant asthma exacerbations (b) No OCS use for asthma (c) Well controlled asthma based on an ACT

At month 12
Mean Change from Baseline in Mini-Asthma Quality of Life Questionnaire (AQLQ) Overall Score
Tidsramme: Baseline and at month 12

The mini-AQLQ overall score is a reduced version of the AQLQ which includes 15 items. The minimally clinically important difference (MCID) is 0.5. The response options for each item are on an equidistant scale of 7 points, where 1 corresponds to the maximum disability and 7 to the absence of disability

Baseline and at month 12

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Efterforskere

  • Studieleder: GSK Clinical Trials, GlaxoSmithKline

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

20. marts 2024

Primær færdiggørelse (Faktiske)

12. februar 2026

Studieafslutning (Anslået)

31. marts 2027

Datoer for studieregistrering

Først indsendt

6. september 2023

Først indsendt, der opfyldte QC-kriterier

15. september 2023

Først opslået (Faktiske)

18. september 2023

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

10. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

6. november 2026

Sidst verificeret

1. november 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • 219871
  • 2023 (U.S. NIH-bevilling/kontrakt)
  • 2023-509026-21-00 (Registry Identifier: CTIS (EU))

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

JA

IPD-planbeskrivelse

Qualified researchers may request access to anonymized individual patient-level data (IPD) and related study documents of the eligible studies via the Data Sharing Portal. Details on GSK's data sharing criteria can be found at: https://www.gsk.com/en-gb/innovation/trials/data-transparency/

IPD-delingstidsramme

Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or terminated asset(s) across all indications.

IPD-delingsadgangskriterier

Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension may be granted, when justified, for up to 6 months.

IPD-deling Understøttende informationstype

  • STUDY_PROTOCOL
  • SAP
  • ICF
  • CSR

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ja

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

produkt fremstillet i og eksporteret fra U.S.A.

Ja

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .